1	Comparison	O
2	with	O
3	alkaline	B
4	phosphatases	I
5	and	O
6	5	B
7	-	I
8	nucleotidase	I
9	.	O

1	Pharmacologic	O
2	aspects	O
3	of	O
4	neonatal	O
5	hyperbilirubinemia	O
6	.	O

1	When	O
2	CSF	O
3	[	O
4	HCO3	O
5	-]	O
6	is	O
7	shown	O
8	as	O
9	a	O
10	function	O
11	of	O
12	CSF	O
13	PCO2	O
14	the	O
15	data	O
16	of	O
17	K	O
18	-	O
19	depleted	O
20	rats	O
21	are	O
22	no	O
23	longer	O
24	displaced	O
25	when	O
26	compared	O
27	to	O
28	controls	O
29	but	O
30	still	O
31	have	O
32	a	O
33	significantly	O
34	greater	O
35	slope	O
36	(	O
37	1	O
38	.	O
39	21	O
40	+/-	O
41	0	O
42	.	O
43	23	O
44	vs	O
45	.	O

1	Flurazepam	O
2	thus	O
3	appears	O
4	to	O
5	be	O
6	an	O
7	effective	O
8	hypnotic	O
9	drug	O
10	with	O
11	the	O
12	optimum	O
13	dose	O
14	for	O
15	use	O
16	in	O
17	general	O
18	practice	O
19	being	O
20	15	O
21	mg	O
22	at	O
23	night	O
24	.	O

1	Beta	O
2	blocking	O
3	agents	O
4	.	O

1	When	O
2	extracorporeal	O
3	CO2	O
4	removal	O
5	approximated	O
6	CO2	O
7	production	O
8	(	O
9	VCO2	O
10	),	O
11	alveolar	O
12	ventilation	O
13	almost	O
14	ceased	O
15	.	O

1	Intravenous	O
2	administration	O
3	(	O
4	25	O
5	mg	O
6	/	O
7	kg	O
8	)	O
9	of	O
10	carbonic	B
11	anhydrase	I
12	inhibitors	O
13	(	O
14	acetazolamide	O
15	,	O
16	methazolamide	O
17	,	O
18	dichlorphenamide	O
19	,	O
20	sulthiame	O
21	)	O
22	induced	O
23	an	O
24	early	O
25	important	O
26	rise	O
27	of	O
28	cortical	O
29	p	O
30	O2	O
31	,	O
32	which	O
33	is	O
34	not	O
35	dependent	O
36	on	O
37	increase	O
38	of	O
39	p	O
40	O2	O
41	and	O
42	p	O
43	CO2	O
44	and	O
45	decrease	O
46	of	O
47	pH	O
48	in	O
49	arterial	O
50	blood	O
51	.	O

1	Teratological	O
2	study	O
3	of	O
4	etoperidone	O
5	in	O
6	the	O
7	rat	O
8	and	O
9	rabbit	O
10	.	O

1	Colorectal	O
2	polyps	O
3	should	O
4	be	O
5	removed	O
6	endoscopically	O
7	whenever	O
8	possible	O
9	.	O

1	The	O
2	variable	O
3	HMG	B
4	dosage	O
5	regimen	O
6	was	O
7	found	O
8	to	O
9	offer	O
10	no	O
11	advantages	O
12	when	O
13	compared	O
14	with	O
15	our	O
16	standard	O
17	daily	O
18	dosage	O
19	regimen	O
20	.	O

1	When	O
2	the	O
3	CO2	O
4	content	O
5	reached	O
6	9	O
7	Vol	O
8	%	O
9	the	O
10	animals	O
11	became	O
12	apathic	O
13	and	O
14	lost	O
15	body	O
16	weight	O
17	.	O

1	Serum	B
2	gamma	I
3	glutamyltransferase	I
4	in	O
5	the	O
6	diagnosis	O
7	of	O
8	liver	O
9	disease	O
10	in	O
11	cattle	O
12	.	O

1	By	O
2	contrast	O
3	,	O
4	secretory	B
5	HI	I
6	antibodies	I
7	were	O
8	not	O
9	demonstrated	O
10	at	O
11	the	O
12	onset	O
13	of	O
14	illness	O
15	in	O
16	any	O
17	of	O
18	the	O
19	patients	O
20	,	O
21	but	O
22	their	O
23	formation	O
24	started	O
25	early	O
26	and	O
27	the	O
28	antibodies	O
29	reached	O
30	maximal	O
31	levels	O
32	about	O
33	10	O
34	days	O
35	after	O
36	onset	O
37	of	O
38	illness	O
39	.	O

1	With	O
2	the	O
3	exception	O
4	of	O
5	virus	O
6	assay	O
7	and	O
8	quantitation	O
9	,	O
10	these	O
11	methods	O
12	are	O
13	simple	O
14	and	O
15	inexpensive	O
16	enough	O
17	to	O
18	be	O
19	done	O
20	in	O
21	typical	O
22	shellfish	O
23	microbiology	O
24	laboratories	O
25	.	O

1	Characteristics	O
2	of	O
3	lipase	B
4	activity	O
5	.	O

1	Takayasu	O
2	'	O
3	s	O
4	disease	O
5	:	O
6	association	O
7	with	O
8	HLA	B
9	-	I
10	B5	I
11	.	O

1	SGPT	B
2	,	O
3	SGOT	B
4	,	O
5	and	O
6	alkaline	B
7	phosphatase	I
8	concentrations	O
9	were	O
10	essentially	O
11	normal	O
12	in	O
13	all	O
14	subjects	O
15	.	O

1	Gamma	B
2	glutamyl	I
3	transpeptidase	I
4	(	O
5	GGTP	B
6	)	O
7	activity	O
8	in	O
9	the	O
10	seminal	O
11	fluid	O

1	Patients	O
2	with	O
3	Parkinson	O
4	'	O
5	s	O
6	disease	O
7	showed	O
8	a	O
9	relatively	O
10	high	O
11	incidence	O
12	to	O
13	psychoses	O
14	during	O
15	drug	O
16	treatment	O
17	(	O
18	51	O
19	.	O
20	47	O
21	%).	O

1	Selective	O
2	stimulation	O
3	of	O
4	central	O
5	alpha	B
6	-	I
7	autoreceptors	I
8	following	O
9	treatment	O
10	with	O
11	alpha	O
12	-	O
13	methyldopa	O
14	and	O
15	FLA	O
16	136	O
17	.	O

1	Anti	O
2	-	O
3	anxiety	O
4	action	O
5	of	O
6	diazepam	O
7	after	O
8	intra	O
9	-	O
10	amygdaloid	O
11	application	O
12	in	O
13	the	O
14	rat	O
15	.	O

1	Abstracts	O
2	.	O

1	Removal	O
2	of	O
3	thick	O
4	,	O
5	permanently	O
6	altered	O
7	mucoas	O
8	is	O
9	recommended	O
10	even	O
11	in	O
12	the	O
13	absence	O
14	of	O
15	squamous	O
16	epithelium	O
17	.	O

1	An	O
2	IgG	B
3	monoclonal	O
4	gammopathy	O
5	was	O
6	present	O
7	in	O
8	the	O
9	serum	O
10	of	O
11	4	O
12	patients	O
13	and	O
14	Bence	O
15	-	O
16	Joanes	O
17	proteinuria	O
18	was	O
19	found	O
20	in	O
21	1	O
22	patient	O
23	.	O

1	Studies	O
2	on	O
3	immunoglobulin	B
4	E	I
5	:	O
6	the	O
7	impact	O
8	of	O
9	a	O
10	sojourn	O
11	with	O
12	Professor	O
13	Dan	O
14	H	O
15	.	O

1	Peroxydase	B
2	reaction	O
3	stains	O
4	were	O
5	negative	O
6	,	O
7	chloroacetate	B
8	esterase	I
9	were	O
10	strongly	O
11	positive	O
12	.	O

1	Ten	O
2	out	O
3	-	O
4	patients	O
5	with	O
6	pustulosis	O
7	palmaris	O
8	et	O
9	plantaris	O
10	were	O
11	examined	O
12	with	O
13	direct	O
14	immunofluorescence	O
15	(	O
16	IF	O
17	)	O
18	technique	O
19	for	O
20	deposition	O
21	of	O
22	fibrinogen	B
23	,	O
24	fibrin	B
25	or	O
26	its	O
27	degradation	O
28	products	O
29	(	O
30	FR	B
31	-	I
32	antigen	I
33	)	O
34	in	O
35	affected	O
36	and	O
37	unaffected	O
38	skin	O
39	,	O
40	together	O
41	with	O
42	heparin	O
43	-	O
44	precipitable	O
45	fraction	O
46	(	O
47	HPF	O
48	),	O
49	cryoglobulin	B
50	and	O
51	total	O
52	plasma	O
53	fibrinogen	B
54	in	O
55	the	O
56	blood	O
57	.	O

1	Of	O
2	600	O
3	mediastinoscopies	O
4	carried	O
5	out	O
6	from	O
7	1966	O
8	to	O
9	1973	O
10	,	O
11	479	O
12	were	O
13	performed	O
14	to	O
15	assess	O
16	the	O
17	operability	O
18	of	O
19	a	O
20	pulmonary	O
21	carcinoma	O
22	.	O

1	A	O
2	mixture	O
3	of	O
4	human	B
5	albumin	I
6	5	O
7	%	O
8	and	O
9	hydroxy	O
10	-	O
11	ethyl	O
12	-	O
13	starch	O
14	was	O
15	used	O
16	as	O
17	a	O
18	solution	O
19	for	O
20	dilution	O
21	.	O

1	In	O
2	the	O
3	matched	O
4	control	O
5	group	O
6	the	O
7	acquisition	O
8	-	O
9	rate	O
10	of	O
11	both	O
12	symptomatic	O
13	and	O
14	asymptomatic	O
15	0acteriuria	O
16	was	O
17	over	O
18	12	O
19	%,	O
20	a	O
21	figure	O
22	similar	O
23	to	O
24	the	O
25	percentage	O
26	of	O
27	women	O
28	present	O
29	in	O
30	the	O
31	practice	O
32	population	O
33	during	O
34	one	O
35	year	O
36	with	O
37	transient	O
38	,	O
39	symptomatic	O
40	,	O
41	and	O
42	persistent	O
43	A	O
44	.	O
45	B	O
46	.	O

1	Late	O
2	complications	O
3	of	O
4	catheterisation	O
5	for	O
6	intravenous	O
7	nutrition	O
8	.	O

1	Prenatal	O
2	diagnosis	O
3	of	O
4	galactosaemia	O
5	.	O

1	Sings	O
2	which	O
3	are	O
4	indicative	O
5	of	O
6	metaplastic	O
7	erythropoiesis	O
8	are	O
9	absent	O
10	.	O

1	False	O
2	positive	O
3	amniotic	B
4	fluid	I
5	alpha	I
6	fetoprotein	I
7	levels	O
8	resulting	O
9	from	O
10	contamination	O
11	with	O
12	fetal	O
13	blood	O
14	:	O
15	results	O
16	of	O
17	an	O
18	experiment	O
19	.	O
